Physician

Mohammad Azam, MD

According to 2025 Medicare claims, Mohammad Azam, MD (NPI: 1184688541) practices pulmonary disease in the Tuscaloosa, AL market, with the plurality of this provider's patient population coming from Tuscaloosa, AL. This provider's primary affiliated billing organization is TUSCALOOSA LUNG & SLEEP CONSULTANTS, PC (NPI: 1447215561; TIN: 63-0778894) and primary practice location at 35401-2029.

Azam's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 705 traditional Medicare patients, billed 6,026 HCPCS/CPT codes, and received $385,866 in Medicare payments. The top billing code was 99233 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes). Part D data shows 5,747 prescription claims across 707 beneficiaries totaling $3,350,119 in drug costs, led by Ofev (Nintedanib Esylate). DME data shows 2,105 claims. Open Payments data shows 162 records totaling $11,785. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $649,322 to $385,866. In contrast, Part D prescription costs have moved sharply higher in recent years, from $771,834 to $3,350,119. For DME billing, reported payments moved sharply higher in recent years, from $100,383 to $200,568.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,198	9,745	$649,322
2016	1,259	10,596	$696,093
2017	1,003	8,842	$588,321
2018	951	7,919	$522,021
2019	936	8,196	$566,306
2020	1,000	9,056	$701,474
2021	840	6,588	$486,147
2022	734	6,166	$417,986
2023	699	5,942	$409,426
2024	705	6,026	$385,866

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	407	3,649	$771,834
2016	430	3,412	$720,887
2017	452	3,702	$1,007,067
2018	484	3,840	$1,069,401
2019	501	3,993	$1,386,846
2020	567	4,638	$2,114,570
2021	607	4,971	$3,062,572
2022	592	5,109	$3,373,823
2023	675	5,476	$3,477,939
2024	707	5,747	$3,350,119

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	588	2,505	$125,450
2016	619	2,650	$159,795
2017	513	2,436	$94,982
2018	436	2,228	$157,906
2019	438	2,185	$160,227
2020	335	2,272	$428,446
2021	350	2,107	$396,150
2022	354	1,903	$378,677
2023	384	2,229	$479,614
2024	354	2,105	$480,007

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	302	1,553	$85
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	369	795	$84
94729	Test to examine how well the lungs exchange gases	328	457	$36
94060	Test to measure expiratory airflow and volume changes before and after medication administration	349	690	$26
88738	Hemoglobin measurement	299	402	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ofev	Nintedanib Esylate	97	2,910	$1,242,928
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	1,129	39,450	$825,800
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	487	17,160	$355,277
Fasenra	Benralizumab	37	1,960	$206,921
Gammaplex	Immun Glob G(Igg)/Gly/Iga 0-50	13	364	$90,641

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	29	$116,035
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	27	$102,197
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	13	117	$99,145
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	66	530	$39,370
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each	Y	N/R	46	$33,973

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	162	$11,785	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohammad Azam, MD?

Tedicare shows public-source Medicare data for Mohammad Azam, MD (NPI 1184688541), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammad Azam, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mohammad Azam, MD?

Mohammad Azam, MD is linked to TUSCALOOSA LUNG & SLEEP CONSULTANTS, PC (billing NPI 1447215561) in the available physician profile data.

Does Mohammad Azam, MD have Open Payments data?

Mohammad Azam, MD has 162 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.